B+
Bull case
20%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
DSGN
Design TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Positive four-week RESTORE-FA data showed dose-dependent increases in endogenous frataxin mRNA and protein alongside improvements across multiple clinical measures, while the company maintains substantial cash resources and advances DT-818 [#SEC-8K-2026-08-03].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.7.
What can break
Analyst revision, target-change, and post-print market-reaction evidence is limited, reducing confidence in near-term directional conclusions.
Momentum
17
Value
41
Sentiment
90
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $25.00 · Bear $7.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $21.71
Why
Momentum17 · Δ7d +3.9
Value41 · Δ7d -0.0
Sentiment90 · Δ7d -2.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -2.7.
Contradictions & invalidation
- • Analyst revision, target-change, and post-print market-reaction evidence is limited, reducing confidence in near-term directional conclusions.
- • FECD Phase 2 biomarker data moved to 2027 because of delayed DT-168 eye-dropper supply [#SEC-8K-2026-08-03].
- • The thesis remains dependent on small clinical cohorts and future biomarker-to-clinical validation.
Catalyst clock
2026-08-03
Q2 2026 operating update and RESTORE-FA redesign
Lead driver: Sentiment · See AI snapshot
Momentum
17
8% active weight
Current posture
7d trendFlat
Δ7d
+3.9
Δ21d
-11.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
90
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.7
Δ21d
+13.5
Why this grade
Composite grade A. Momentum 17.2 / Value 40.6 / Sentiment 89.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$665.24M
Beta
1.64
Shares Out
62.58M
P/E (TTM) · Derived
-8.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.60
Rev YoY
-
EPS YoY
-3.9%
Gross Margin
-
Op Margin
-
Net Debt
-$218.31M
Current Ratio
18.86
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data